Zimbabwe has rejected a significant US health deal worth 367 million US dollars (£272m) over five years over the United States' insistence on confidential biological samples.
This rejection became public following a government memo from December was disclosed, revealing that President Emmerson Mnangagwa felt the deal was "unbalanced".
An official representative has since clarified that the United States was demanding access to genetic material for scientific study and commercial purposes but was unwilling to share the benefits from any future medical innovations.
"We are forced to start the difficult and regrettable task of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for continued talks to find a agreement acceptable to all parties so the nation's critical HIV programme can proceed.
Broader Context
This development follows a similar case in neighbouring Kenya, where a court blocked a related health funding agreement after legal challenges were filed about the safety of Kenyans' medical information.
Since resuming the presidency last year, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had administered aid for the American government, but Trump argued its spending was "inefficient" and his administration was pursuing government-to-government agreements to boost openness and accountability.
Based on statements, 16 African countries have to date agreed to these new agreements, representing more than $18.3bn in new funding.
Specifics of the Rejected Deal
The money for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy through US-supported programmes," the Ambassador commented.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data indefinitely, with no corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.
"Effectively, our country would provide the raw materials for scientific discovery with no assurance that the final treatments would be accessible to our people if a new health crisis emerge."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the global health body and its push of bilateral health agreements were undermining frameworks already established via the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to deal with potential pandemics.
"This mechanism is designed to ensure that when a nation contributes its data, the benefits – such as medicines and cures – are distributed fairly, not monopolised solely by those with the resources to create them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage further discussions with our US partners on how future co-operation could be arranged in a manner that honours the independence and dignity of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but recommended that negotiations need to persist given that much of the nation's Aids initiatives relied on foreign aid.
"In cases where specific concerns arise, such as those relating to information security or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," the group said.
The situation underscores the continuing challenges between accepting much-needed foreign assistance and protecting national sovereignty in an increasingly data-driven world.